NCT04811196 2025-05-29
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
University Health Network, Toronto
Phase 1 Completed
Clinical Trials
3 trialsNCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT02269293 2021-04-23
Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination With Paclitaxel and Carboplatin in Patients With Advanced Ovarian or Endometrial Cancers
Memorial Sloan Kettering Cancer Center
Phase 1 Completed